News

Both Adaptimmune and Replay have placed their bets on targeting cancer testis antigens for synovial sarcoma and myxoid/round cell liposarcoma cell therapy.

Review top news and interview highlights from the week ending August 11, 2023.

The assistant member in the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center spoke about A2B530's mechanism of action and how it could represent a leap forward in the application of CAR T-cell agents for patients with solid tumors.

The chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.

The first participant was dosed with LBL-033 in April 2023 in Nanjing Lead Biolabs's ongoing trial in China.

The professor of medicine and pediatrics at Washington University in St. Louis discussed the current investigative landscape for cell therapy in treating sarcomas.

KMA.CAR-T is directed at Kappa Myeloma Antigen, a receptor exclusively appearing on myeloma cells in kappa-type MM.

The TIL therapy's PDUFA date has been pushed back to February 24, 2024.

The chief medical officer of Celularity discussed MLASC and a new analysis of gene and protein signatures from patients treated in legacy clinical trials that he presented at ASGCT’s 2023 conference.

LION-CS101, the study evaluating gene therapy AB-1003, is currently recruiting patients aged 18 years through 65 years with LGMD2I/R9 who have a confirmed mutation in FKRP.

At dose level 2, 3 of 4 participants had increases of β-Gal activity to normal levels for up to 12 months.

The associate professor at MD Anderson Cancer Center discussed challenges with developing cell therapy for sarcoma and how TCR NK therapy's unique characteristics may prove useful.

Jennifer Gori, PhD, vice president of research at Prime Medicine, discussed what distinguishes prime editing from other forms of gene editing.

XyloCor Therapeutics’ encoberminogene rezmadenovec (XC001) has shown positive data among the 2 highest doses assessed, with the 1×10^11 viral particles dose selected for continued study.

The professor of medicine at University of California San Diego discussed the advent of gene therapy into the field of cardiac medicine.

The phase 2 ALPHA2 trial of ALLO-501A should complete enrollment in 2024.

Review top news and interview highlights from the week ending August 4, 2023.

Four years after submitting its initial BLA for remestemcel-L for steroid-refractory acute graft versus host disease, Mesoblast has encountered another hurdle toward possible approval.

TCR2 Therapeutics’ T cell therapy gavocabtagene autoleucel showed encouraging antitumor activity in the phase 1 portion of an ongoing trial, with an identified recommended dose for the next phase.

The phase 1/2 trial features 3 phases, with new sites expected to open in the coming months. VX-264 uses the same stem cell-derived islets used in the VX-880 program in type 1 diabetes.

The gene-edited cell therapy OTL-200 was approved in Europe in 2020.

The assistant professor at MD Anderson Cancer Center discussed progress of the phase 1/2 trial being conducted at the center.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The associate professor at Medical College of Wisconsin discussed current studies evaluating cilta-cel and ongoing research.

The initiation of dosing the second cohort in Ultragenyx’s study was recommended by the Data Safety Monitoring Board after a review of safety results from the trial’s first cohort.

LEXEO also recently completed dosing in the first cohort of a trial for Friedreich’s ataxia cardiomyopathy.

Taysha Gene Therapies previously reported the dosing of the first patient with TSHA-102 in June 2023.

The chief scientific officer at Omega Therapeutics discussed the importance of understanding more about and researching epigenetics.

Nicole Paulk, PhD, the CEO, founder, and president of Siren Biotechnology, discussed research she presented at ASGCT’s 2023 conference.

AVC-201 utilizes the company’s UniCAR switchable technology platform.